Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response

Oncogene

Volumn 34, Issue 29, 2015, Pages 3860-3870

  Erin, N ^a   Podnos, A ^b   Tanriover, G ^a   Duymus O ^a   Cote, E ^b   Khatri, I ^b   Gorczynski, R M ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VIMENTIN; ANTIGENS, CD200; AUTACOID; CD200R1 PROTEIN, MOUSE; CYTOKINE; LEUKOCYTE ANTIGEN; OREXIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VISCERAL METASTASIS; ANIMAL; BAGG ALBINO MOUSE; DISEASE COURSE; EXPERIMENTAL MAMMARY NEOPLASM; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALIA; MURINAE; MUS;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CYTOKINES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-6; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEUTROPHIL INFILTRATION; OREXIN RECEPTORS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937467914     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.317     Document Type: Article

References (54)

1. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH et al. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 2000; 13: 233-242.
2. Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden PA. CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol 2004; 172: 7744-7749.
3. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003; 171: 3034-3046.
4. Boudakov I, Liu J, Fan N, Gulay P, Wong K, Gorczynski RM. Mice lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-alpha and mixed leukocyte culture responses by CD200. Transplantation 2007; 84: 251-257.
5. Gorczynski RM, Chen Z, Hu J, Kai Y, Lei J. Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumor cells in C57BL/6 mice. Clin Exp Immunol 2001; 126: 220-229.
6. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008; 180: 699-705.
7. Memarian A, Nourizadeh M, Masoumi F, Tabrizi M, Emami AH, Alimoghaddam K et al. Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia. Tumor Biol 2013; 34: 531-542.
8. Wong KK, Brenneman F, Chesney A, Spaner DE, Gorczynski RM. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. Cancer Res 2012; 72: 4931-4943.
9. Rygiel TP, Karnam G, Goverse G, van der Marel AP, Greuter MJ, van Schaarenburg RA et al. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor. Oncogene 2012; 31: 2979-2988.
10. Stumpfova M, Ratner D, Desciak EB, Eliezri YD, Owens DM. The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res 2010; 70: 2962-2972.
11. Colmont CS, Benketah A, Reed SH, Hawk NV, Telford WG, Ohyama M et al. CD200-expressing human basal cell carcinoma cells initiate tumor growth. Proc Natl Acad Sci USA 2013; 110: 1434-1439.
12. Talebian F, Liu JQ, Liu Z, Khattabi M, He Y, Ganju R et al. Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS One 2012; 7: e31442.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
14. Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetly R, Dash S. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol 2011; 178: 838-852.
15. Erin N, Akdas BG, Harms JF, Clawson GA. Vagotomy enhances experimental metastases of 4THMpc breast cancer cells and alters substance P level. Regul Pept 2008; 151: 35-42.
16. Erin N, Zhao W, Bylander J, Chase G, Clawson G. Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells. Breast Cancer Res Treat 2006; 99: 351-364.
17. Erin N, Wang N, Xin P, Bui V, Weisz J, Barkan GA et al. Altered gene expression in breast cancer liver metastases. Int J Cancer 2009; 124: 1503-1516.
18. Erin N, Kale S, Tanriover G, Koksoy S, Duymus O, Korcum AF. Differential characteristics of heart, liver, and brain metastatic subsets of murine breast carcinoma. Breast Cancer Res Treat 2013; 139: 677-689.
19. Gorczynski RM, Clark DA, Erin N, Khatri I. Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice. Breast Cancer Res Treat 2011; 130: 49-60.
20. Podnos A, Clark DA, Erin N, Yu K, Gorczynski RM. Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6. Breast Cancer Res Treat 2012; 136: 117-127.
21. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM et al. Downregulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000; 290: 1768-1771.
22. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
23. Dvorak HF. Tumors. wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
24. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-1313.
25. Murohashi M, Hinohara K, Kuroda M, Isagawa T, Tsuji S, Kobayashi S et al. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br J Cancer 2010; 102: 206-212.
26. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 117: 3988-4002.
27. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139: 693-706.
28. Tamm I, Cardinale I, Krueger J, Murphy JS, May LT, Sehgal PB. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med 1989; 170: 1649-1669.
29. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008; 68: 9087-9095.
30. Lin G, Wang J, Lao X, Wang J, Li L, Li S et al. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother 2012; 35: 337-343.
31. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14: e218-e228.
32. Storci G, Sansone P, Mari S, D'Uva G, Tavolari S, Guarnieri T et al. TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol 2010; 225: 682-691.
33. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010; 102: 639-644.
34. Geng Y, Chandrasekaran S, Hsu JW, Gidwani M, Hughes AD, King MR. Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. PLoS One 2013; 8: e54959.
35. Montagut C, Tusquets I, Ferrer B, Corominas JM, Bellosillo B, Campas C et al. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006; 13: 607-616.
36. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196: 129-134.
37. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22: 371-383.
38. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008; 226: 205-218.
39. Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, Feng Y et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 2003; 63: 6042-6050.
40. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996; 88: 536-541.
41. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
42. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 2013; 109: 2705-2713.
43. West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 2013; 108: 155-162.
44. Gorczynski RM, Chen Z, Diao J, Khatri I, Wong K, Yu K et al. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 2010; 123: 405-415.
45. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ et al. The origin of vimentin expression in invasive breast cancer: epithelial mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?. J Pathol 2005; 206: 451-457.
46. Gorczynski RM, Chen Z, Khatri I, Podnos A, Yu K. Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling. Breast Cancer Res Treat 2013; 142: 271-282.
47. Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM et al. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 2006; 177: 1526-1533.
48. Ryckman C, Vandal K, Rouleau P, Talbot M, Philippe A, Tessier PA. Proinflammatory activities of S100: Proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003; 170: 3233-3242.
49. Maru Y. Which came first tumor cells or macrophages?. Cell Adh Migr 2007; 1: 107-109.
50. Kim H, Kang HJ, Lee H, Lee ST, Yu MH, Kim H et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J. Proteome Res 2009; 8: 1368-1379.
51. Hiratsuka S, Ishibashi S, Tomita T, Watanabe A, Akashi-Takamura S, Murakami M et al. Primary tumours modulate innate immune signalling to create premetastatic vascular hyperpermeability foci. Nat Commun 2013; 4: 1853.
52. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H. Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol 2013; 15: 891-903.
53. Gorczynski RM, Chen Z, He W, Khatri I, Sun Y, Yu K et al. Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 2009; 183: 1560-1568.
54. Erin N, Boyer PJ, Bonneau RH, Clawson GA, Welch DR. Capsaicin-mediated denervation of sensory neurons promotes mammary tumor metastasis to lung and heart. Anticancer Res 2004; 24: 1003-1009.